BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Brings Powerful Capabilities to Modern Clinical Trials

Company: RYAH Group Inc. (RYAH)
Category: Stock Spotlights

RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics. These provide next-generation capabilities that allow for more control of variables within a clinical setting, which is especially significant in modern cannabis clinical trials. While historical emphasis has largely been centered on potential harmful effects, today’s research teams are exploring the use of cannabis to address a wide range of chronic conditions, while it holds significant potential for pain relief. The future of cannabis study with the addition of dose-measuring devises looks promising, and RYAH is front-and-center on the trend. “RYAH has begun to work with an international oncology clinic in the UK on one of the largest clinical trials of its kind. The company will be studying the safety and efficacy of cannabis and hemp for the treatment of chronic pain,” reads a recent article. “Recently the company successfully shipped 10,000 dry-herb cartridges and QR codes in its initial shipment for the clinic’s pilot run. The complete order includes potentially thousands of RYAH Smart inhalers and millions of proprietary cartridges for the use of this study over the next five years.”

To view the full article, visit https://ibn.fm/gjPn1

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050